Invitae Corporation (NVTAQ)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Invitae Corporation (NVTAQ) with AI Score 41/100 (Weak). Invitae Corporation is a medical genetics company providing genetic information to improve healthcare. The company filed for Chapter 11 reorganization in February 2024. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Invitae Corporation (NVTAQ) Healthcare & Pipeline Overview
Invitae Corporation provides genetic testing services across various clinical areas, including hereditary cancer and rare diseases, serving patients, healthcare providers, and biopharma companies. Currently undergoing Chapter 11 reorganization, the company faces significant financial challenges within the competitive medical diagnostics market.
Investment Thesis
Invitae Corporation's Chapter 11 filing introduces significant uncertainty regarding its future. Key value drivers include its comprehensive genetic testing services and partnerships within the healthcare ecosystem. Growth catalysts involve potential restructuring efficiencies and strategic realignment. However, the company faces substantial risks, including navigating bankruptcy proceedings, maintaining operational stability, and addressing financial obligations. Investors should closely monitor the reorganization process and assess the long-term viability of Invitae's business model. The company's negative profit margin of -601.6% and current market capitalization of $0.00B highlight the financial challenges it faces.
Based on FMP financials and quantitative analysis
Key Highlights
- Filed for Chapter 11 reorganization on February 13, 2024, indicating significant financial distress.
- Offers a wide range of genetic tests across various clinical areas, including hereditary cancer, precision oncology, and rare diseases.
- Serves a diverse customer base, including patients, healthcare providers, and biopharma companies.
- Gross margin of 19.2% indicates challenges in achieving profitability.
- Profit margin of -601.6% reflects substantial losses and financial instability.
Competitors & Peers
Strengths
- Comprehensive genetic test menu.
- Established relationships with healthcare providers.
- Proprietary technology and data analytics.
- Strong brand recognition.
Weaknesses
- Chapter 11 bankruptcy filing.
- Negative profit margins.
- High operating expenses.
- Significant debt burden.
Catalysts
- Ongoing: Restructuring efforts to reduce debt and improve financial stability.
- Upcoming: Potential emergence from Chapter 11 bankruptcy with a viable reorganization plan.
- Ongoing: Strategic partnerships to expand market reach and service offerings.
Risks
- Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.
- Potential: Failure to secure necessary financing for restructuring.
- Potential: Loss of key customers or partnerships.
- Ongoing: Intense competition in the genetic testing market.
- Potential: Regulatory changes and reimbursement pressures.
Growth Opportunities
- Expansion into New Therapeutic Areas: Invitae can explore expanding its genetic testing services into emerging therapeutic areas such as neurodegenerative diseases and cardiovascular health. The market for genetic testing in these areas is growing, driven by advancements in research and increasing awareness of genetic risk factors. This expansion could provide Invitae with new revenue streams and market opportunities, although significant investment in research and development would be required.
- Strategic Partnerships with Biopharma Companies: Collaborating with biopharmaceutical companies to develop companion diagnostics and personalized treatment strategies represents a significant growth opportunity. The increasing focus on precision medicine drives demand for genetic testing to identify patients who are most likely to benefit from specific therapies. These partnerships can provide Invitae with access to new markets and revenue streams, while also enhancing its reputation and credibility within the healthcare industry.
- Geographic Expansion into Emerging Markets: Expanding its services into emerging markets, particularly in Asia and Latin America, could drive significant growth for Invitae. These regions have a growing demand for genetic testing due to increasing healthcare awareness and access to medical services. However, entering these markets requires careful consideration of regulatory requirements, cultural differences, and competition from local players.
- Development of Integrated Digital Health Solutions: Integrating genetic testing results with digital health platforms and tools can enhance patient engagement and improve healthcare outcomes. This includes developing mobile apps, online portals, and telehealth services that provide patients with personalized insights and support. The market for digital health solutions is rapidly growing, driven by increasing adoption of mobile technology and the need for more efficient and accessible healthcare services. This integration can differentiate Invitae from competitors and enhance customer loyalty.
- Focus on Rare Disease Diagnostics: Expanding its focus on rare disease diagnostics can provide Invitae with a niche market opportunity. Rare diseases often require specialized genetic testing to identify the underlying cause and guide treatment decisions. By offering comprehensive testing services for rare diseases, Invitae can address an unmet need in the healthcare market and establish itself as a leader in this area. This focus requires expertise in rare disease genetics and collaboration with specialized healthcare providers and patient advocacy groups.
Opportunities
- Expansion into new therapeutic areas.
- Strategic partnerships with biopharma companies.
- Geographic expansion into emerging markets.
- Development of integrated digital health solutions.
Threats
- Intense competition in the genetic testing market.
- Regulatory changes and reimbursement pressures.
- Technological advancements that could render existing tests obsolete.
- Economic downturns that could reduce demand for genetic testing.
Competitive Advantages
- Comprehensive test menu covering a wide range of clinical areas.
- Established relationships with healthcare providers and biopharma companies.
- Proprietary technology and data analytics capabilities.
- Brand recognition and reputation in the genetic testing market.
About NVTAQ
Invitae Corporation, founded in 2010 and formerly known as Locus Development, Inc., is a medical genetics company headquartered in San Francisco, California. The company focuses on providing comprehensive genetic information to enhance healthcare decisions across the United States, Canada, and internationally. Invitae offers a range of genetic tests covering various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics. These tests are designed to assist in diagnosis, treatment planning, and risk assessment for patients. In addition to genetic testing, Invitae provides digital health solutions and health data services, catering to patients, healthcare providers, biopharma companies, and other partners. The company aims to integrate genetic information into mainstream medical practice, making it more accessible and affordable. However, on February 13, 2024, Invitae and its affiliates filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey, indicating substantial financial distress.
What They Do
- Provides genetic tests for hereditary cancer risk assessment.
- Offers genetic testing for precision oncology to guide cancer treatment decisions.
- Delivers genetic screening and diagnostic tests for women's health.
- Provides genetic testing for rare diseases to identify underlying causes.
- Offers pharmacogenomics testing to optimize medication selection and dosage.
- Develops digital health solutions to enhance patient engagement.
- Provides health data services to support research and development.
Business Model
- Generates revenue through the sale of genetic testing services to patients and healthcare providers.
- Partners with biopharma companies to develop and commercialize companion diagnostics.
- Offers digital health solutions and health data services on a subscription or fee-for-service basis.
Industry Context
Invitae Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market is driven by the growing prevalence of genetic disorders and the need for early and accurate diagnosis. Competitive landscape includes established players like Roche and smaller, specialized genetic testing companies. Invitae's Chapter 11 filing reflects the challenges of scaling and achieving profitability in this competitive environment.
Key Customers
- Patients seeking genetic testing for risk assessment or diagnosis.
- Healthcare providers ordering genetic tests for their patients.
- Biopharma companies utilizing genetic testing for drug development and clinical trials.
Financials
Chart & Info
Invitae Corporation (NVTAQ) stock price: Price data unavailable
Latest News
No recent news available for NVTAQ.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVTAQ.
Price Targets
Wall Street price target analysis for NVTAQ.
MoonshotScore
What does this score mean?
The MoonshotScore rates NVTAQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Kenneth D. Knight
CEO
Kenneth D. Knight serves as the Chief Executive Officer of Invitae Corporation. His professional background and educational details are not provided in the source data. As CEO, he is responsible for overseeing the company's strategic direction, operational performance, and financial results. His leadership is critical during the company's Chapter 11 reorganization process.
Track Record: Kenneth D. Knight's track record at Invitae is difficult to assess given the company's recent Chapter 11 filing. Key decisions during his tenure will likely focus on restructuring the company's operations, reducing debt, and securing new financing. The success of these efforts will determine the company's long-term viability.
NVTAQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Invitae Corporation (NVTAQ) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may be undergoing financial distress or restructuring. Trading on the OTC Other tier carries higher risks compared to exchanges like NYSE or NASDAQ due to less stringent listing standards and potentially lower liquidity. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- Chapter 11 bankruptcy introduces significant uncertainty about the company's future.
- Potential for delisting from the OTC market.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Verify the company's financial condition and review available financial statements.
- Assess the company's Chapter 11 reorganization plan and potential outcomes.
- Research the background and experience of the company's management team.
- Evaluate the company's competitive position and market outlook.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Established history as a provider of genetic testing services.
- Existing relationships with healthcare providers and biopharma companies.
- Proprietary technology and data analytics capabilities.
- Continued operation during the Chapter 11 reorganization process.
NVTAQ Healthcare Stock FAQ
What does Invitae Corporation do?
Invitae Corporation is a medical genetics company that provides genetic information to improve healthcare decisions. The company offers a range of genetic tests across various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics. These tests are designed to assist in diagnosis, treatment planning, and risk assessment. Invitae serves patients, healthcare providers, and biopharma companies, aiming to integrate genetic information into mainstream medical practice. However, the company filed for Chapter 11 reorganization in February 2024 due to financial challenges.
What do analysts say about NVTAQ stock?
Given Invitae Corporation's Chapter 11 bankruptcy filing, analyst coverage and ratings are likely limited or suspended. Key valuation metrics such as price-to-earnings ratio are not meaningful due to the company's negative profitability. Investors should focus on the company's restructuring efforts, potential for reorganization, and long-term viability. Analyst consensus is difficult to gauge due to the uncertainty surrounding the company's future.
What are the main risks for NVTAQ?
The main risks for Invitae Corporation include the ongoing Chapter 11 bankruptcy proceedings, potential liquidation, and failure to secure necessary financing for restructuring. The company also faces risks related to intense competition in the genetic testing market, regulatory changes, and reimbursement pressures. Additionally, the company's high debt burden and negative profit margins pose significant financial challenges. Investors should carefully consider these risks before investing in NVTAQ.
What are the key factors to evaluate for NVTAQ?
Invitae Corporation (NVTAQ) currently holds an AI score of 41/100, indicating low score. Key strength: Comprehensive genetic test menu.. Primary risk to monitor: Ongoing: Chapter 11 bankruptcy proceedings and potential liquidation.. This is not financial advice.
How frequently does NVTAQ data refresh on this page?
NVTAQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven NVTAQ's recent stock price performance?
Recent price movement in Invitae Corporation (NVTAQ) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Comprehensive genetic test menu.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider NVTAQ overvalued or undervalued right now?
Determining whether Invitae Corporation (NVTAQ) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying NVTAQ?
Before investing in Invitae Corporation (NVTAQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be incomplete due to the company's Chapter 11 status.
- Financial data may not be up-to-date due to the company's financial distress.